社区获得性肺炎成人患者的头孢他啶复方新诺明治疗模式和疗效:一项真实世界的跨国回顾性研究。

IF 3.7 Q2 INFECTIOUS DISEASES
JAC-Antimicrobial Resistance Pub Date : 2024-05-27 eCollection Date: 2024-06-01 DOI:10.1093/jacamr/dlae078
Alex Soriano, Matteo Bassetti, Charalambos Gogos, Tristan Ferry, Raul de Pablo, Wajeeha Ansari, Michal Kantecki, Bernd Schweikert, Gustavo Luna, Francesco Blasi
{"title":"社区获得性肺炎成人患者的头孢他啶复方新诺明治疗模式和疗效:一项真实世界的跨国回顾性研究。","authors":"Alex Soriano, Matteo Bassetti, Charalambos Gogos, Tristan Ferry, Raul de Pablo, Wajeeha Ansari, Michal Kantecki, Bernd Schweikert, Gustavo Luna, Francesco Blasi","doi":"10.1093/jacamr/dlae078","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings.</p><p><strong>Methods: </strong>Anonymized patient data were extracted from hospital records of adults with CAP who received ≥4 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain.</p><p><strong>Results: </strong>The dataset included 185 patients (58.9% male; mean age 62.2 years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI/PORT score or physician judgement. <i>Streptococcus pneumoniae</i> (<i>n </i>= 44; 23.8%) and <i>Staphylococcus aureus</i> [MSSA (<i>n </i>= 15) and MRSA (<i>n </i>= 14)] were the most frequently identified pathogens. Clinical response occurred in 151 (81.6%) patients overall, and in 104 (81.3%) severe CAP patients. Response within ≤4 and >4 days occurred in 79 (42.7%) and 62 (33.5%) patients (unknown, <i>n </i>= 10), respectively. Twenty (10.8%) patients required readmission within 30 days. Thirty-day all-cause mortality rates were 9.7% (<i>n </i>= 18) overall and 10.2% (<i>n </i>= 13) in severe CAP. In sensitivity analysis using ICU admission as a more objective marker of severe CAP (<i>n </i>= 75), clinical response and 30 day mortality occurred in 57 (76.0%) and 10 (13.3%) patients, respectively. Overall, clinical response to ceftaroline fosamil was associated with >60% shorter length of ICU stay (3.6 versus 9.2 days), and >30% lower hospital costs ($8449 versus $12 559) versus non-responders.</p><p><strong>Conclusions: </strong>Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11128847/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study.\",\"authors\":\"Alex Soriano, Matteo Bassetti, Charalambos Gogos, Tristan Ferry, Raul de Pablo, Wajeeha Ansari, Michal Kantecki, Bernd Schweikert, Gustavo Luna, Francesco Blasi\",\"doi\":\"10.1093/jacamr/dlae078\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings.</p><p><strong>Methods: </strong>Anonymized patient data were extracted from hospital records of adults with CAP who received ≥4 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain.</p><p><strong>Results: </strong>The dataset included 185 patients (58.9% male; mean age 62.2 years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI/PORT score or physician judgement. <i>Streptococcus pneumoniae</i> (<i>n </i>= 44; 23.8%) and <i>Staphylococcus aureus</i> [MSSA (<i>n </i>= 15) and MRSA (<i>n </i>= 14)] were the most frequently identified pathogens. Clinical response occurred in 151 (81.6%) patients overall, and in 104 (81.3%) severe CAP patients. Response within ≤4 and >4 days occurred in 79 (42.7%) and 62 (33.5%) patients (unknown, <i>n </i>= 10), respectively. Twenty (10.8%) patients required readmission within 30 days. Thirty-day all-cause mortality rates were 9.7% (<i>n </i>= 18) overall and 10.2% (<i>n </i>= 13) in severe CAP. In sensitivity analysis using ICU admission as a more objective marker of severe CAP (<i>n </i>= 75), clinical response and 30 day mortality occurred in 57 (76.0%) and 10 (13.3%) patients, respectively. Overall, clinical response to ceftaroline fosamil was associated with >60% shorter length of ICU stay (3.6 versus 9.2 days), and >30% lower hospital costs ($8449 versus $12 559) versus non-responders.</p><p><strong>Conclusions: </strong>Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.</p>\",\"PeriodicalId\":14594,\"journal\":{\"name\":\"JAC-Antimicrobial Resistance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11128847/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAC-Antimicrobial Resistance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jacamr/dlae078\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAC-Antimicrobial Resistance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jacamr/dlae078","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:这项多中心、观察性、回顾性病历审查研究评估了在常规护理环境下头孢他啶福沙米在成人社区获得性肺炎(CAP)住院患者中的治疗模式和效果:研究人员从巴西、哥伦比亚、法国、希腊、意大利、俄罗斯和西班牙等国的医院病历中提取了匿名患者数据,这些患者均为CAP成人患者,连续接受了≥4次头孢他啶福沙米尔静脉滴注:数据集包括 185 名患者(58.9% 为男性;平均年龄 62.2 岁),其中 128 人(69.2%)根据 CURB-65、PSI/PORT 评分或医生判断患有重症 CAP。肺炎链球菌(44 人;23.8%)和金黄色葡萄球菌[MSSA(15 人)和 MRSA(14 人)]是最常见的病原体。151 例(81.6%)患者出现临床应答,104 例(81.3%)重症 CAP 患者出现临床应答。≤4天和>4天内出现应答的患者分别为79人(42.7%)和62人(33.5%)(未知,n = 10)。20名患者(10.8%)需要在30天内再次入院。30天内全因死亡率总体为9.7%(n = 18),重症CAP为10.2%(n = 13)。在将入住重症监护室作为重症 CAP 更客观标志的敏感性分析中(n = 75),分别有 57 例(76.0%)和 10 例(13.3%)患者出现临床反应和 30 天死亡率。总体而言,与无应答者相比,头孢他啶福沙米尔临床应答者的重症监护室住院时间缩短60%以上(3.6天对9.2天),住院费用降低30%以上(8449美元对12559美元):在欧洲和拉丁美洲,头孢他啶福沙米尔对治疗成人 CAP(包括重症 CAP)有效。与无应答者相比,头孢他啶福沙米的临床反应与医疗资源使用的减少有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ceftaroline fosamil treatment patterns and outcomes in adults with community-acquired pneumonia: a real-world multinational, retrospective study.

Background: This multicentre, observational, retrospective chart review study assessed ceftaroline fosamil treatment patterns and outcomes in adults hospitalized with community-acquired pneumonia (CAP) in usual care settings.

Methods: Anonymized patient data were extracted from hospital records of adults with CAP who received ≥4 consecutive IV ceftaroline fosamil doses at sites in Brazil, Colombia, France, Greece, Italy, Russia and Spain.

Results: The dataset included 185 patients (58.9% male; mean age 62.2 years), of whom 128 (69.2%) had severe CAP defined by CURB-65, PSI/PORT score or physician judgement. Streptococcus pneumoniae (n = 44; 23.8%) and Staphylococcus aureus [MSSA (n = 15) and MRSA (n = 14)] were the most frequently identified pathogens. Clinical response occurred in 151 (81.6%) patients overall, and in 104 (81.3%) severe CAP patients. Response within ≤4 and >4 days occurred in 79 (42.7%) and 62 (33.5%) patients (unknown, n = 10), respectively. Twenty (10.8%) patients required readmission within 30 days. Thirty-day all-cause mortality rates were 9.7% (n = 18) overall and 10.2% (n = 13) in severe CAP. In sensitivity analysis using ICU admission as a more objective marker of severe CAP (n = 75), clinical response and 30 day mortality occurred in 57 (76.0%) and 10 (13.3%) patients, respectively. Overall, clinical response to ceftaroline fosamil was associated with >60% shorter length of ICU stay (3.6 versus 9.2 days), and >30% lower hospital costs ($8449 versus $12 559) versus non-responders.

Conclusions: Ceftaroline fosamil was effective in treating adults with CAP, including severe CAP, in Europe and Latin America. Clinical response to ceftaroline fosamil was associated with reductions in healthcare resource use compared with non-responders.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
0
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信